No Patent Board Sanctions For Bass; Celgene Denied
This article was originally published in Scrip
Executive Summary
Celgene failed to convince the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) to impose sanctions against Kyle Bass, chief investment officer at Hayman Capital Management, and his self-created Coalition for Affordable Drugs, and dismiss his inter partes review (IPR) petitions on the grounds of abuse of process and improper use of the proceedings.